Sarepta Historical Income Statement
| SRPT Stock | USD 126.66 2.14 1.66% |
Historical analysis of Sarepta Therapeutics income statement accounts such as Gross Profit of 1.1 B, Other Operating Expenses of 1.6 B, Research Development of 921.3 M or Total Operating Expenses of 1.4 B can show how well Sarepta Therapeutics performed in making a profits. Evaluating Sarepta Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sarepta Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Sarepta Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sarepta Therapeutics is a good buy for the upcoming year.
Sarepta |
About Sarepta Income Statement Analysis
Sarepta Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sarepta Therapeutics shareholders. The income statement also shows Sarepta investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Sarepta Therapeutics Income Statement Chart
Sarepta Therapeutics Income Statement is one of the three primary financial statements used for reporting Sarepta's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Sarepta Therapeutics revenue and expense. Sarepta Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Sarepta Therapeutics' Cost Of Revenue is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 16.7 M in 2024, despite the fact that EBITDA is likely to grow to (254.4 M). Add Fundamental
Total Revenue
Total revenue comprises all receipts Sarepta Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sarepta Therapeutics. It is also known as Sarepta Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Sarepta Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sarepta Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.At this time, Sarepta Therapeutics' Cost Of Revenue is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 16.7 M in 2024, despite the fact that EBITDA is likely to grow to (254.4 M).
| 2023 | 2024 (projected) | Non Recurring | 199.2M | 209.2M | Interest Income | 67.7M | 71.0M |
Sarepta Therapeutics income statement Correlations
Click cells to compare fundamentals
Sarepta Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sarepta Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 52.9M | 34.9M | 37.6M | 62.7M | 58.9M | 61.8M | |
| Interest Expense | 30.7M | 59.9M | 63.5M | 53.2M | 22.0M | 23.1M | |
| Selling General Administrative | 284.8M | 317.9M | 282.7M | 451.4M | 481.9M | 506.0M | |
| Total Revenue | 380.8M | 540.1M | 701.9M | 933.0M | 1.2B | 1.3B | |
| Gross Profit | 324.2M | 476.7M | 604.8M | 793.0M | 1.1B | 1.1B | |
| Other Operating Expenses | 903.2M | 1.1B | 1.2B | 1.5B | 1.5B | 1.6B | |
| Operating Income | (522.3M) | (564.2M) | (449.7M) | (536.2M) | (267.8M) | (254.4M) | |
| Ebit | (522.3M) | (564.2M) | (449.7M) | (536.2M) | (326.7M) | (310.4M) | |
| Research Development | 560.9M | 722.3M | 771.2M | 877.1M | 877.4M | 921.3M | |
| Ebitda | (469.4M) | (529.3M) | (412.1M) | (473.5M) | (267.8M) | (254.4M) | |
| Total Operating Expenses | 846.6M | 1.0B | 1.1B | 1.3B | 1.4B | 1.4B | |
| Income Before Tax | (713.9M) | (553.1M) | (418.9M) | (690.0M) | (520.1M) | (494.1M) | |
| Total Other Income Expense Net | (191.6M) | 11.1M | 30.8M | (153.8M) | (252.3M) | (239.7M) | |
| Net Income | (715.1M) | (554.1M) | (418.8M) | (703.5M) | (536.0M) | (509.2M) | |
| Cost Of Revenue | 56.6M | 63.4M | 97.0M | 140.0M | 150.3M | 157.9M | |
| Income Tax Expense | 1.2M | 1.1M | (168K) | 13.5M | 15.9M | 16.7M | |
| Net Income From Continuing Ops | (715.1M) | (554.1M) | (418.8M) | (703.5M) | (690.9M) | (656.3M) | |
| Non Operating Income Net Other | (19.0M) | (8.3M) | 11.1M | 40.8M | 46.9M | 49.2M | |
| Net Income Applicable To Common Shares | (715.1M) | (554.1M) | (418.8M) | (703.5M) | (633.1M) | (601.5M) | |
| Interest Income | 7.2M | 3.0M | 354K | 16.5M | 67.7M | 71.0M | |
| Net Interest Income | (23.4M) | (57.0M) | (63.2M) | (36.8M) | 44.2M | 46.4M | |
| Selling And Marketing Expenses | 2.8M | 2.2M | 7.7M | 14.6M | 28.6M | 30.0M | |
| Tax Provision | 1.2M | 1.1M | (168K) | 13.5M | 29.1M | 30.6M | |
| Reconciled Depreciation | 30.5M | 26.9M | 38.0M | 41.9M | 43.6M | 31.6M |
Currently Active Assets on Macroaxis
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.80) | Revenue Per Share 13.456 | Quarterly Revenue Growth 0.535 | Return On Assets (0.05) | Return On Equity (0.86) |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.